Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Kumi Oshima, Yoshinobu Kanda, Takuya Yamashita, Satoshi Takahashi, Takehiko Mori, Chiaki Nakaseko, Katsumichi Fujimaki, Akira Yokota, Shin Fujisawa, Takafumi Matsushima, Hiroyuki Fujita, Tohru Sakura, Shinichiro Okamoto, Atsuo Maruta, Hisashi Sakamaki

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT). Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse. Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT with a cumulative incidence of 2.3%. Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95% confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95% CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95% CI = 2.62-12.0, P = 9.2 × 10-6), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95% CI = 1.21-5.46, P = .014). The 3-year overall survival (OS) after CNS relapse was 18%. In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS. Three of 7 patients were alive without systemic relapse, resulting in 3-year survival after CNS relapse of 46%. Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.

Original languageEnglish
Pages (from-to)1100-1107
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number10
DOIs
Publication statusPublished - 2008 Oct

Fingerprint

Hematopoietic Stem Cell Transplantation
Leukemia
Central Nervous System
Recurrence
Confidence Intervals
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Group Psychotherapy
Cell- and Tissue-Based Therapy
Acute Myeloid Leukemia
Disease-Free Survival
History
Databases
Drug Therapy

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Central nervous system
  • Leukemia
  • Relapse

ASJC Scopus subject areas

  • Transplantation

Cite this

Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. / Oshima, Kumi; Kanda, Yoshinobu; Yamashita, Takuya; Takahashi, Satoshi; Mori, Takehiko; Nakaseko, Chiaki; Fujimaki, Katsumichi; Yokota, Akira; Fujisawa, Shin; Matsushima, Takafumi; Fujita, Hiroyuki; Sakura, Tohru; Okamoto, Shinichiro; Maruta, Atsuo; Sakamaki, Hisashi.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 10, 10.2008, p. 1100-1107.

Research output: Contribution to journalArticle

Oshima, K, Kanda, Y, Yamashita, T, Takahashi, S, Mori, T, Nakaseko, C, Fujimaki, K, Yokota, A, Fujisawa, S, Matsushima, T, Fujita, H, Sakura, T, Okamoto, S, Maruta, A & Sakamaki, H 2008, 'Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 14, no. 10, pp. 1100-1107. https://doi.org/10.1016/j.bbmt.2008.07.002
Oshima, Kumi ; Kanda, Yoshinobu ; Yamashita, Takuya ; Takahashi, Satoshi ; Mori, Takehiko ; Nakaseko, Chiaki ; Fujimaki, Katsumichi ; Yokota, Akira ; Fujisawa, Shin ; Matsushima, Takafumi ; Fujita, Hiroyuki ; Sakura, Tohru ; Okamoto, Shinichiro ; Maruta, Atsuo ; Sakamaki, Hisashi. / Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 10. pp. 1100-1107.
@article{c1e2a2f38fc94e9bb2fd4fc1dd226210,
title = "Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT). Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse. Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT with a cumulative incidence of 2.3{\%}. Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95{\%} confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95{\%} CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95{\%} CI = 2.62-12.0, P = 9.2 × 10-6), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95{\%} CI = 1.21-5.46, P = .014). The 3-year overall survival (OS) after CNS relapse was 18{\%}. In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS. Three of 7 patients were alive without systemic relapse, resulting in 3-year survival after CNS relapse of 46{\%}. Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Central nervous system, Leukemia, Relapse",
author = "Kumi Oshima and Yoshinobu Kanda and Takuya Yamashita and Satoshi Takahashi and Takehiko Mori and Chiaki Nakaseko and Katsumichi Fujimaki and Akira Yokota and Shin Fujisawa and Takafumi Matsushima and Hiroyuki Fujita and Tohru Sakura and Shinichiro Okamoto and Atsuo Maruta and Hisashi Sakamaki",
year = "2008",
month = "10",
doi = "10.1016/j.bbmt.2008.07.002",
language = "English",
volume = "14",
pages = "1100--1107",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

AU - Oshima, Kumi

AU - Kanda, Yoshinobu

AU - Yamashita, Takuya

AU - Takahashi, Satoshi

AU - Mori, Takehiko

AU - Nakaseko, Chiaki

AU - Fujimaki, Katsumichi

AU - Yokota, Akira

AU - Fujisawa, Shin

AU - Matsushima, Takafumi

AU - Fujita, Hiroyuki

AU - Sakura, Tohru

AU - Okamoto, Shinichiro

AU - Maruta, Atsuo

AU - Sakamaki, Hisashi

PY - 2008/10

Y1 - 2008/10

N2 - Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT). Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse. Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT with a cumulative incidence of 2.3%. Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95% confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95% CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95% CI = 2.62-12.0, P = 9.2 × 10-6), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95% CI = 1.21-5.46, P = .014). The 3-year overall survival (OS) after CNS relapse was 18%. In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS. Three of 7 patients were alive without systemic relapse, resulting in 3-year survival after CNS relapse of 46%. Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.

AB - Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT). Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse. Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT with a cumulative incidence of 2.3%. Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95% confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95% CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95% CI = 2.62-12.0, P = 9.2 × 10-6), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95% CI = 1.21-5.46, P = .014). The 3-year overall survival (OS) after CNS relapse was 18%. In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS. Three of 7 patients were alive without systemic relapse, resulting in 3-year survival after CNS relapse of 46%. Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Central nervous system

KW - Leukemia

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=51649130416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649130416&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.07.002

DO - 10.1016/j.bbmt.2008.07.002

M3 - Article

VL - 14

SP - 1100

EP - 1107

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -